NYSE:ABT
Abbott Laboratories
Abbott Laboratories's revenue grew 5.7% in fiscal 2025 to $44.3B while operating margin rose to 18.2%. Free cash flow was $7.4B, 16.7% of revenue.Summary generated from Abbott Laboratories's SEC filings. Latest annual report filed Feb 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$44.3B
Revenue growth+5.7%
Revenue, 5-yr CAGR+5.1%
Gross margin56.4%
Operating margin18.2%
Net margin14.7%
ROIC11.2%
Return on equity13.1%
Debt / equity0.25
Free cash flow$7.4B
FCF margin16.7%
Share count change+0.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 43.1 | 43.7 | 40.1 | 42.0 | 44.3 |
| Operating income | 8.4 | 8.4 | 6.5 | 6.8 | 8.1 |
| Net income | 7.1 | 6.9 | 5.7 | 13.4 | 6.5 |
| Free cash flow | 8.6 | 7.8 | 5.1 | 6.4 | 7.4 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KRegulation FD disclosure
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 28, 2026 - 8-KResults of operations and financial condition
Jul 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 29, 2026 - 8-KDirector or officer change
Apr 27, 2026 - 8-KOther events
Apr 17, 2026